UCB

paper paperclips
Favicon Fierce Pharma

FDA's response letter salvo sheds light on drug refusal process

The FDA's response letter salvo offers an in-depth view into the high-stakes discussions that decide whether a medicine will ever make it to market.
cellos without players

UCB-Novartis Parkinson's asset fails to improve symptoms in ph. 2

Dec 16, 2024 3:19pm
success failure signposts

UCB's tau drug flunks Alzheimer's trial days after Roche's exit

Nov 1, 2024 6:01am
arrow back backwards u-turn turn around reverse

Roche tosses out $120M tau prospect, returning rights to UCB

Oct 22, 2024 8:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Biogen, UCB report phase 3 lupus win after failing earlier trial

Sep 24, 2024 6:00am
ringing alarm clock times up

100 days with John Crowley: Behind BIO’s new structure & vision

Jun 25, 2024 9:05am